International Clinical Trial: Efficacy and Management Optimization of First-Line Chemo-Immunotherapy in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132266) titled 'Efficacy and Management Optimization of First-Line Chemo-Immunotherapy in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study' on Sept. 11.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)

Condition: Extensive-Stage Small Cell Lung Cancer

Intervention: Group PD-L1 (Atezolizumab / Durvalumab):N/A

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-09-15

Target Sample Size: Group PD-L1 (Atezolizumab / Durvalumab):650;Group PD-...